Alembic Pharmaceuticals Limited has announced the successful completion of an unannounced onsite Bioequivalence inspection by the United States Food and Drug Administration (USFDA) at its Vadodara, Gujarat facility. The inspection, which took place from August 31, 2026, to September 10, 2026, concluded with no Form 483 observations. This outcome is a positive affirmation of the company’s adherence to stringent quality and regulatory standards.
USFDA Inspection Successfully Completed
Alembic Pharmaceuticals Limited is pleased to report the successful conclusion of an unannounced, onsite inspection conducted by the United States Food and Drug Administration (USFDA). The inspection focused on the Company’s Bioequivalence Facility located in Vadodara, Gujarat.
Key Outcome: No Observations
The inspection, which took place from August 31, 2026, to September 10, 2026, resulted in a highly favorable outcome. Alembic Pharmaceuticals Limited has confirmed that the inspection concluded with no Form 483 observations. This is a significant achievement, underscoring the company’s commitment to maintaining high standards of quality and regulatory compliance.
Significance for the Company
The successful completion of this USFDA inspection without any observations is a strong testament to the robust systems and processes in place at Alembic Pharmaceuticals’ Bioequivalence Facility. It reinforces the company’s standing as a reliable manufacturer of pharmaceutical products meeting global regulatory requirements.
Source: BSE
